Recent Updates
Recently added Catalysts
IMCC Positive Sentiment

IM Cannabis to Report third Quarter 2025 Financial Results on Thursday, November 13th at 9:00am ETUSA - EnglishIsrael - English

Key Takeaway: IM Cannabis Corp. will announce its third quarter 2025 financial results on November 13, 2025. The report will cover operational and financial performance for the period ending September 30, 2025. IMC operates in Israel and Germany, focusing on premium medical cannabis products and sustainable growth. The company aims to enhance its market presence through a data-driven approach.
Price reaction · baseline $1.33 (2025-11-05 close) · hit pre-market · clean, no other IMCC news in the window
day 0 close
-0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • IM Cannabis is expanding its operations in key markets.
  • The company is focused on sustainable and profitable growth.
  • IMC has a robust data-driven approach to its business.
  • The upcoming financial report may highlight positive trends.

Full Press Release Details

TORONTO and GLIL YAM, Israel,Nov. 6, 2025/PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the third quarter 2025 ended September 30, 2025, on Thursday, November 13, 2025, before the market opens.

About IM Cannabis Corp.

IMC (Nasdaq:IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Company Contact:

Frequently Asked Questions

When will IM Cannabis report its Q3 2025 results?

IM Cannabis will report its Q3 2025 financial results on November 13, 2025.

What markets does IM Cannabis operate in?

IM Cannabis operates primarily in Israel and Germany.

What is the focus of IM Cannabis Corp.?

IM Cannabis focuses on providing premium cannabis products to medical patients.

How does IM Cannabis ensure product quality?

IM Cannabis leverages a data-driven approach and a controlled supply chain.

Last updated: Nov 6, 2025